Use of test
Deletions of 1p and 19q are associated with tumours with oligodendroglial components and is pathognomonic for a distinct glioma entity under the WHO classification system. The co-deletion is due to an unbalanced translocation - t(1;19)(q10;p10). The panel also includes testing for EGFR amplication.
Demonstration of co-deletion of 1p and 19q in oligodendroglioma has been shown to be associated with a favourable response to therapy, in addition to being required for accurate diagnosis. EGFR amplification may be associated with poorer prognosis.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to enumerate the 1p and 19q deletion status.
Requesting the test
This test is usually requested by an oncologist. EGFR amplification is usually requested concurrently.
Download the solid tumour somatic mutation request form.
Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.
Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-15). The request should be accompanied by the somatic mutation request form (above) and a copy of the original histopathology report.
5 business days (after receipt of sample by the laboratory).
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.
Click here for our billing policy.